blood glucose; however, he did not experience a single episode of hypoglycemia (defined as blood glucose level below 70 mg/ dL). Over the days to follow, he climbed Nido de Condores (5550 meters), Plaza Cólera (5970), and on the 7th day he reached Aconcagua. The final episode of activation of predictive insulin delivery suspension was recorded at an altitude of 5600 meters. The patient recalls that he experienced and addressed a slightly elevated blood sugar level (between 140 and 200 mg/dL) later on; since the "suspend before low" option was set at 70 mg/dL, the SmartGuard had "no chance" to act. According to the patient, the CGM system performed well, and showed no significant discrepancy between data from the CGM system and hand blood glucose meter (Contour® Plus Link 2.4, Ascensia, Basel, Switzerland).
During the 7-day expedition the patient experienced just 1 episode of hypoglycemia (blood sugar level of 61 mg/dL); the predictive insulin delivery suspension was activated 11 times.
In summary, the insulin pump with predictive low glucose management technology performed well at high altitude; however, further studies are needed before any recommendation for its usage at altitude can be made.
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